UPDATE: 3 March 2024, 8:40 P.M. ET. In February 2024, Biogen took Aduhelm off the market, citing financial concerns. Although the drug did receive…
Following sharp criticisms of the FDA’s broad approval of Aduhelm for all patients with Alzheimer’s, the agency has narrowed the drug’s label to those…
Today, the experimental Eli Lilly drug donanemab received the FDA’s “breakthrough therapy designation” based on its potential to treat Alzheimer’s disease. The FDA granted…
Image: Aduhelm, Biogen/AP. “The approach I’ve been taking is that each decision about whether or not to offer this as a treatment has to…
UPDATE: 3 March 2024, 8:26 P.M. ET. In February 2024, Biogen took Aduhelm off the market, citing financial concerns. Although the drug did receive…
Retired neurologist Daniel Gibbs speaks about his own Alzheimer’s diagnosis, his unusual and severe case of side effects in aducanumab (Aduhelm) clinical trials, and…
The FDA’s approval of Biogen’s new anti-amyloid drug Aduhelm was a landmark moment for Alzheimer’s — and it comes with no small amount of…
UPDATE: 3 March 2024, 8:33 P.M. ET. In February 2024, Biogen took Aduhelm off the market, citing financial concerns. Although the drug did receive…
Looking for answers about Alzheimer’s treatment Aduhelm (generic name aducanumab)? Here’s a primer on what it is, what it does, and more, according to…
As an aducanumab trial participant, Phil Gutis, a reporter with early-stage Alzheimer’s, was part of Aduhelm’s journey to FDA approval. Doctors can soon start…
Cinical trial investigators for aducanumab (Aduhelm) discuss the significance of the drug’s recent FDA approval, the controversy surrounding its efficacy, and the uncertainty ahead….
“Historic moment:” Today, the FDA gave Biogen’s investigational Alzheimer’s drug aducanumab its approval, with the requirement that they conduct a post-approval trial. UPDATE: 3…
Geri Taylor, a participant in the aducanumab (Aduhelm) clinical trial, and her husband Jim share insights about taking part in the research. UPDATE: 3…
Image: Phil Gutis receives an aducanumab infusion while carrying out his “silly shoe challenge.” Phil Gutis reflects on the significance of participating in the…
Biogen’s aducanumab — a human antibody-based drug that targets beta-amyloid plaques, which are found in the brains of people with Alzheimer’s — has gone…